Cabozantinib in combination w/ nivolumab and ipilimumab of IMDC intermediate or poor risk significantly improved PFS vs PBO

Bookmark and Share
Published: 12 Sep 2022
Views: 29
Rating:
Save
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

Dr Toni Choueiri, presents his COSMIC-313 phase 3 study, of cabozantinib in combination with nivolumab and ipilimumab previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk.

The results demonstrated cabozantinib + nivolumab + ipilimumab significantly improved PFS versus placebo + nivolumab + ipilimumab in previously untreated aRCC of IMDC intermediate or poor risk.